Yes, you need an enclomiphene prescription. Enclomiphene is a prescription drug, not a supplement, and no FDA-approved enclomiphene product exists. In the US it is available only as a compounded medication, and compounded medications are not FDA-approved. The legitimate path runs through repeat morning testosterone tests, a check of LH and FSH (the pituitary hormones that signal the testes), a clinician's evaluation and a licensed pharmacy.
Key takeaways
- Enclomiphene is prescription-only, and in the US it is available only as a compounded medication, which is not FDA-approved.
- Guidelines call for two early-morning total testosterone tests on separate occasions, plus symptoms, before diagnosing low testosterone (AUA, 2018).
- Trials enrolled men with secondary (signalling) low testosterone and measured hormone levels and sperm counts over short periods, not long-term outcomes.
- At New Blue, enclomiphene is a hormone pathway with lab work and a live visit with an independent licensed clinician, and not everyone qualifies.
Do you need a prescription for enclomiphene?
Yes. Enclomiphene is a drug, and a legitimate pharmacy dispenses it only on a valid prescription from a licensed prescriber.
FDA describes enclomiphene citrate as a small molecule related to clomiphene citrate (FDA PCAC transcript, 2022). Both are SERMs (selective estrogen receptor modulators), drugs that block estrogen's effect in some tissues but not others. Enclomiphene is not a peptide, though it often appears in peptide catalogs.
Products labelled "for research use only" are sold as lab chemicals, not medicines. Buying them skips a prescriber who confirms the diagnosis, baseline labs that show whether and why testosterone is low, and a licensed pharmacy accountable for what is in the capsule.
Is enclomiphene FDA-approved? What its legal status actually is
No. There is no FDA-approved enclomiphene product, and compounded enclomiphene is not FDA-approved. It was studied in phase 3 randomized trials (BJU International, 2015) but never approved. Our guide to enclomiphene side effects and what regulators found covers that history.
Compounding means a licensed pharmacy prepares a medication from a raw active ingredient, called a bulk drug substance, for a patient with a prescription. Compounded medications are prepared by state-licensed 503A compounding pharmacies or FDA-registered 503B outsourcing facilities. For 503A pharmacies, the framework works like this:
- Section 503A of the federal Food, Drug, and Cosmetic Act directs FDA to build a list of bulk substances that can be used in compounding, called the 503A bulks list (FDA interim policy, 2025).
- In June 2022, FDA's Pharmacy Compounding Advisory Committee discussed enclomiphene citrate as a substance nominated for that list, with a nominated use of increasing serum testosterone (FDA PCAC transcript, 2022). A nomination or committee discussion is not an approval.
- While the list is developed, an FDA interim policy applies. Its Category 1 covers nominated substances under evaluation, and FDA does not intend to take action against compounding with a Category 1 substance if the policy's conditions are met (FDA interim policy, 2025).
- FDA's categories list, updated May 14, 2026, has three groups: under evaluation, raising significant safety concerns, and nominated without adequate support (FDA categories list, 2026).
The point most sales pages miss: Category 1 is an enforcement posture, not an approval, and a substance's category can change, so check enclomiphene citrate's current entry on the FDA list directly. Even a Category 1 listing is not approval, and it says nothing about whether the drug is right for you. Status can change over time.
What lab work is reviewed before enclomiphene is prescribed?
A clinician first confirms that testosterone is truly low, then checks LH and FSH to see where the problem starts. If fertility matters, a reproductive health evaluation is part of the picture.
- Confirm the number. The American Urological Association (AUA) treats a total testosterone below 300 ng/dL (nanograms per deciliter) as a reasonable cut-off. It says low testosterone should be diagnosed only after two measurements on separate occasions, both early in the morning, preferably at the same lab with the same method (AUA, 2018). Our guide to testosterone blood test timing covers fasting and repeats.
- Match it to symptoms. Diagnosis requires both a low measurement and relevant symptoms or signs (AUA, 2018).
- Check the signal. Luteinizing hormone (LH) and follicle-stimulating hormone (FSH), called gonadotropins, come from the pituitary gland. LH tells the testes to make testosterone, and FSH supports sperm production. When fasting morning testosterone is low, the AUA/ASRM male infertility guideline points to evaluating them (AUA/ASRM, 2024). Enclomiphene raises LH and FSH (BJU International, 2013), so it depends on a signal that can still respond.
- Find the cause. For hypogonadotropic hypogonadism, meaning low testosterone driven by weak pituitary signalling, the guideline says clinicians should evaluate the cause and treat based on the diagnosis (AUA/ASRM, 2024).
- Account for fertility. Men with testosterone deficiency who are interested in fertility should have a reproductive health evaluation (AUA, 2018). A clinician may include a semen analysis in that evaluation.
Who is usually considered for enclomiphene, and who is not
Enclomiphene is usually considered for men with symptoms, repeatedly low morning testosterone and a secondary pattern on labs, often men who want to protect fertility. It is usually not a fit for men with testicular failure or low readings that don't hold up on repeat testing.
| Pattern | Where the problem sits | Typical LH and FSH | Fit with how enclomiphene works |
|---|---|---|---|
| Secondary hypogonadism | Pituitary or brain signalling | Low or not raised enough | Signal can be increased; this is the studied population |
| Primary hypogonadism | The testes themselves | Usually high | Signal is already high; the testes may not respond more |
Usually considered:
- Men with confirmed low testosterone, symptoms and a secondary pattern. The phase 2 trial enrolled men with secondary hypogonadism (Fertility and Sterility, 2014), and the phase 3 studies enrolled overweight men aged 18 to 60 with secondary hypogonadism (BJU International, 2015).
- Men who care about current or future fertility. The AUA/ASRM guideline says clinicians should not prescribe testosterone therapy to them. It conditionally allows aromatase inhibitors (drugs that lower the body's estrogen production), hCG (human chorionic gonadotropin, a hormone that acts like LH), SERMs or a combination for infertile men with low testosterone, and notes that SERMs are not FDA-approved for use in men, though clomiphene is often prescribed off-label (AUA/ASRM, 2024).
Usually not a candidate:
- Men with primary hypogonadism, where the testes may not respond to a stronger signal. The 2025 meta-analysis excluded studies that included primary hypogonadism (Archives of Endocrinology and Metabolism, 2025).
- Men whose low reading isn't confirmed on repeat morning testing.
- Women, anyone under 21 and anyone who needs emergency care. This pathway is for men, and New Blue serves adults 21 and over.
- Men whose history or medications lead the clinician to decide against it.
Enclomiphene is not better or worse than testosterone therapy. The two work differently, as our comparison of enclomiphene vs testosterone replacement lays out. Appropriateness is always a clinical decision made by an independent licensed clinician.
What does the research on enclomiphene actually show?
Studies in men with secondary hypogonadism, including randomized trials, found that enclomiphene raised testosterone, LH and FSH, and the published trial titles report preserved sperm counts compared with topical testosterone. The trials were short and measured lab values, not long-term outcomes.
| Study | Type | Population | What it measured |
|---|---|---|---|
| BJU International, 2013 | Pharmacology study, 48 men | Secondary hypogonadism | Testosterone, LH, FSH, drug levels |
| Fertility and Sterility, 2014 | Randomized phase 2, 3 months | Secondary hypogonadism | Testosterone and sperm vs topical testosterone and placebo |
| BJU International, 2015 | Two randomized, double-blind phase 3 studies | Overweight men 18 to 60 | Testosterone, LH, FSH, sperm counts vs testosterone gel |
| Archives of Endocrinology and Metabolism, 2025 | Systematic review and meta-analysis | Functional hypogonadism; primary excluded | Pooled randomized trials of clomiphene or enclomiphene |
The 2013 study adds one detail worth knowing: LH and FSH rose above the normal range, while total testosterone rose into it (BJU International, 2013). Oligospermia, in the 2014 title, means low sperm count.
The limits matter as much. The endpoints were hormone levels and sperm counts, not years of symptoms or health outcomes. One trial in the meta-analysis was open-label, meaning participants knew what they received (Archives of Endocrinology and Metabolism, 2025). In the Wiehle trial included in the meta-analysis, adverse events were similar across the enclomiphene, testosterone gel and placebo groups (Archives of Endocrinology and Metabolism, 2025). In a follow-up letter, the meta-analysis authors call for long-term, patient-centered randomized trials (Archives of Endocrinology and Metabolism, 2025).
How access works through New Blue
Enclomiphene can be prescribed through telehealth where state rules allow, but telehealth changes where the visit happens, not the steps a careful evaluation requires. At New Blue, enclomiphene hormone support is a hormone pathway with lab work and a live visit with an independent licensed clinician. Not everyone qualifies. Eligibility depends on your intake, labs and clinical review, and that's how it should work.
- Complete a structured intake covering history, symptoms, medications and fertility goals.
- Complete lab work as the clinician requests.
- Attend a live visit with an independent licensed clinician, who reviews your labs and history and decides whether enclomiphene is appropriate.
- If prescribed, a licensed partner pharmacy ships the medication directly to you. Follow your clinician's guidance and pharmacy instructions.
- Follow-up and repeat labs happen as your clinician decides.
Consultation timing varies by clinician availability. New Blue is a technology and administrative services platform. Medical services are provided by independent licensed clinicians; medications are dispensed only if prescribed. New Blue is LegitScript certified. Availability varies by state; check the state availability page.
If your request isn't accepted, the hold on your card is released and nothing is charged. If you're not prescribed after your visit, what you paid comes back except the part that covers your lab work and clinician visit. Details are in the refund policy. For current pricing, see the enclomiphene hormone support page.
Red flags when shopping for an enclomiphene prescription
The clearest warning signs are skipped labs, no live clinician contact and any claim that the drug is approved or the prescription is certain.
- No labs, or a single afternoon test treated as enough.
- No live clinician contact for a hormone medication.
- "Research use only" labels or dose menus you pick from yourself.
- Promises that a prescription is fast, easy or certain.
- Claims of FDA approval for compounded enclomiphene, which is not FDA-approved.
- No clear statement that a licensed pharmacy prepares and dispenses the medication.
Questions worth asking any provider: Will you check LH and FSH and repeat my morning testosterone? How do my fertility goals change the plan? Is the medication prepared by a state-licensed 503A compounding pharmacy or an FDA-registered 503B outsourcing facility?
Frequently Asked Questions
Do you need a prescription for enclomiphene?
Yes. Enclomiphene is a prescription drug, not a supplement, and a legitimate pharmacy dispenses it only on a valid prescription from a licensed prescriber. Products sold "for research use only" skip the prescriber, the baseline labs and the licensed pharmacy.
Is enclomiphene FDA-approved?
No. There is no FDA-approved enclomiphene product, and compounded enclomiphene is not FDA-approved. FDA's Pharmacy Compounding Advisory Committee discussed it in 2022 as a substance nominated for the 503A bulks list, and a nomination or committee discussion is not an approval.
Is enclomiphene the same as Clomid?
No. Clomid is a brand of clomiphene citrate, a mix of two closely related forms of one molecule, and enclomiphene is one of those forms. FDA describes enclomiphene citrate as related to clomiphene citrate, but it is not a generic or equivalent of Clomid.
Can I use labs I already have?
Possibly, but the clinician decides what is needed. The guideline standard is two total testosterone measurements, both early in the morning, on separate occasions, so a single or afternoon test may need repeating. LH and FSH are also needed if they were not checked.
Can enclomiphene be prescribed online?
Generally yes, where state telehealth and pharmacy rules allow. At New Blue, enclomiphene requires lab work and a live visit with an independent licensed clinician, never a form alone. Availability varies by state, so check the state availability page.
Sources
- Evaluation and Management of Testosterone Deficiency: AUA Guideline. Journal of Urology, 2018. https://doi.org/10.1016/j.juro.2018.03.115
- Diagnosis and Treatment of Infertility in Men: AUA/ASRM Guideline (2020; Amended 2024). American Urological Association / American Society for Reproductive Medicine, 2024. https://www.auanet.org/documents/Guidelines/PDF/2024%20Guidelines/Male%20Infertility%20Unabridged%20Final.pdf
- Enclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized phase II clinical trial comparing topical testosterone. Fertility and Sterility, 2014. https://pubmed.ncbi.nlm.nih.gov/25044085/
- Testosterone Restoration by Enclomiphene Citrate in Men with Secondary Hypogonadism: Pharmacodynamics and Pharmacokinetics. BJU International, 2013. https://pubmed.ncbi.nlm.nih.gov/23875626/
- Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone: restoration instead of replacement. BJU International, 2015. https://doi.org/10.1111/bju.13337
- Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trials. Archives of Endocrinology and Metabolism, 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12510335/
- Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A. U.S. Food and Drug Administration, 2025. https://www.fda.gov/media/174456/download
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (categories list). U.S. Food and Drug Administration, 2026. https://www.fda.gov/media/94155/download
- Pharmacy Compounding Advisory Committee meeting transcript, June 8, 2022 (Section 503A Bulk Drug Substances List: enclomiphene citrate). U.S. Food and Drug Administration, 2022. https://www.fda.gov/media/161294/download
Medical disclaimer: This article is educational and is not medical advice. Treatment decisions, including whether enclomiphene is appropriate for you, are made by an independent licensed clinician based on your intake, labs and clinical review. New Blue Health is a technology and administrative services platform, not a medical provider.
Related treatment guide
Related reading
Content review & editorial standards
This page is educational content from the New Blue Health Editorial Team. It is checked under the New Blue Health Content Review Policy and Editorial Policy and should not replace individualized medical advice from a licensed clinician. For how we evaluate evidence, see Evidence Methodology and Clinical Sources & References.